From study start-up through close-out, our medical monitors provide continuous, data-informed oversight that reduces protocol deviations, accelerates timelines, and enhances data quality, helping studies reach milestones safely and efficiently.
Note: Bar thickness represents number of studies per sponsor.
Sponsors of all sizes allows seamless adaptation to any structure, pace, or governance model.
Enable MMS to function as an embedded extension of the clinical development team, ensuring true continuity.
Capability to manage projects of any size and complexity ensures strong oversight across all phases of oncology drug development.
Experience across diverse mechanisms of action and study designs enables confident, informed decision-making throughout the trial lifecycle.
A team of oncologists with 25+ years of clinical experience, exclusively dedicated to oncology, delivers the deep expertise and sharper insights required for high-quality medical oversight.
Medical Data Reviewer
Mr. Landry is a Medical Data Reviewer who joined the MMS team in October 2024 and has been a great addition ever since. He is skilled at identifying data discrepancies and manipulating data to prepare it for analysis, ensuring accuracy and consistency throughout the review lifecycle.
With a strong background in Information Technology, Mr. Landry’s attention to detail, proficiency in data management, and expertise in tools such as Spotfire and Power BI have been invaluable to the team. He has developed a tracking system for medical review that automatically calculates completeness, improving oversight and workflow efficiency. In addition, he created an Excel-based model to generate swimmer plots, enabling clear visualization of the patient journey throughout the clinical trial.
His ability to automate and optimize medical review processes continues to enhance the accuracy, efficiency, and overall quality of data review across clinical projects.
Senior Clinical Scientist
Ms. Araujo is a Clinical Scientist with 5 years of experience supporting medical monitoring in clinical trials across solid tumors and hematologic malignancies. Her work focuses on data review, subpopulation analysis, and signal detection, contributing to the identification of emerging safety trends and ensuring patient protection. She has been actively involved in multiple oncology programs, supporting data-driven decision-making and maintaining high standards of data quality throughout all study phases.
At Medical Monitoring Solutions (MMS), she has supported Phase I–III trials, leading activities such as data review and reconciliation, patient eligibility assessments, SAE narrative evaluations, and responses to protocol-related queries. Her collaborative approach and strong analytical skills have been key to meeting project milestones and maintaining the scientific integrity of each study.
Ms. Araujo earned her Bachelor of Science in Biology, with minors in Chemistry and Neuroscience, from the University of Washington, and completed a Master’s in Regulatory Affairs at Johns Hopkins University.
Medical Imaging Reviewer Director
Dr. Rocío Araujo is a board-certified Radiologist with over 30 years of clinical experience and 3 years in clinical development, specializing in imaging review and medical monitoring for oncology trials. She brings strong clinical insight into tumor response assessment, disease progression, and imaging-based endpoints.
At Medical Monitoring Solutions (MMS), Dr. Araujo provides medical monitoring for Phase I to III oncology studies, including medical data review, eligibility and protocol deviation assessments, SAE narrative evaluation, and input on protocols and safety management plans. She is experienced with RECIST 1.1, modified RECIST, RANO, modified RANO, and other tumor response criteria, supporting accurate and consistent efficacy evaluation.
She is proficient in Spotfire and JReview, she enhances data visualization and strengthens imaging driven clinical interpretation.
Dr. Araujo earned her Medical Degree at San Martín de Porres University in Lima, Perú, and completed her Radiology Fellowship at Universidad Nacional de Trujillo.
Associate Medical Director
Dr. Sally Corrales is a board-certified Oncologist with over 13 years of experience in clinical oncology and cancer research. Her expertise spans a wide range of solid and hematologic malignancies, and she has served as both a Principal Investigator and sub-investigator in multiple clinical trials, including studies focused on HER2-positive breast cancer, venous thromboembolism prevention, and metastatic cancers.
After relocating to the United States in 2022, Dr. Corrales became actively involved in a patient advocacy project, where she worked to enhance patient education, engagement, and access to oncology clinical trials. This experience deepened her commitment to improving the patient experience in cancer research and development. She joined MMS in May 2024, where she now supports Phase 1–2 solid tumor trials, including ovarian, breast, and gastric cancers. In this role, she manages and reviews safety narratives, investigator brochures, clinical study reports, and conducts medical data reviews across multiple studies with tight timelines, ensuring both scientific rigor and regulatory excellence.
Dr. Corrales earned her Medical Degree from the University of San Antonio de Abad del Cusco and completed her Oncology Fellowship at Federico Villarreal University.
Senior Medical Director
Dr. Rocío Reategui is a board-certified Oncologist with over 25 years of clinical experience across solid tumors. She brings extensive expertise in medical affairs and clinical development, with a strong background in medical monitoring, clinical data review, and regulatory-facing deliverables. As one of the earliest leaders at MMS, she has provided continuity, scientific rigor, and senior medical oversight across multiple global oncology programs.
At MMS, Dr. Reategui supports early- and late-phase trials by overseeing end-to-end medical monitoring, guiding clinical interpretation and safety assessments, and leading medical oversight during critical milestones such as database locks, interim analyses, and publication-driven work streams. She partners closely with clinical operations, safety, and biometrics teams to resolve complex clinical questions and ensures consistent standards of medical review, including oversight of CRO medical monitoring services when contracted by sponsors.
Dr. Reategui earned her Medical Degree and completed her Oncology Fellowship at the National University Federico Villarreal in Lima, Peru, and holds a Master’s in Molecular Oncology from the National Centre for Oncological Research (CNIO) in Madrid, Spain.
Founder & Clinical Development Consultant
Dr. Mosher is a board-certified Hematologist with over 25 years of clinical experience and 21 years in clinical development. She has deep expertise in immuno-oncology, monoclonal antibodies, cell and genetherapies, and antibody-drug conjugates.
Throughout her career, Dr. Mosher has held senior leadership roles across CROs, biotech, and pharmaceutical companies, providing strategic clinical development consulting, interim CMO support, and leadership in IND, NDA, and BLA submissions. Since 2004, she has contributed to the approval of multiple therapies, delivering medical oversight, regulatory guidance, and strategic direction while leading global programs and multidisciplinary teams.
At MMS, Dr. Mosher partners with sponsors from the earliest stages of development, helping to define clinical strategies, establish robust development plans, and strengthen clinical development capabilities.
